Nonmalignant Hematologic Disorders

Review expert perspectives on key findings in nonmalignant hematologic disorders presented at the 2017 ASH annual meeting.

Share

Program Content

Activities

  • HAVEN 4 PK Run-In
    HAVEN 4 Preliminary Analysis: Pharmacokinetic Run-in Cohort of Phase III Study of Q4W Emicizumab in Hemophilia A
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2017

    Expires: December 10, 2018

  • HAVEN 2: Emicizumab in Pediatric PwHA
    HAVEN 2: Second Interim Analysis of Phase III Single-Arm Study of Emicizumab in Pediatric Patients With Hemophilia A and Factor VIII Inhibitors
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

    Expires: December 11, 2018

  • Cost Impact of Rivaroxaban
    EINSTEIN CHOICE: Cost Impact Analysis of Continued Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

    Expires: December 11, 2018

  • SUSTAIN: Time to First SCPC
    SUSTAIN Subgroup Analysis: Time to First Sickle Cell–Related Pain Crisis in Patients With SCD Receiving Crizanlizumab vs Placebo
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

    Expires: December 11, 2018

  • Eltrombopag for Persistent vs Chronic ITP
    Eltrombopag in Adult Patients With Persistent or Chronic ITP: Analysis of a Phase IV Open-Label Study
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2017

    Expires: December 12, 2018

  • SELECT-D: Anticoagulants in VTE
    SELECT-D: Dalteparin vs Rivaroxaban Anticoagulation Therapy for Patients With Cancer at Risk of VTE Recurrence
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2017

    Expires: December 12, 2018

  • Edoxaban vs Dalteparin for VTE
    Hokusai VTE-Cancer Study: Edoxaban vs Dalteparin for VTE in Adult Cancer Patients
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2017

    Expires: December 13, 2018

  • Poor Response to IST in Severe AA
    Retrospective Chart Review of Treatment Patterns, Healthcare Resource Utilization in Patients With Severe Aplastic Anemia and Poor Response to Immunosuppression
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2017

    Expires: December 13, 2018

  • Avatrombopag in Chronic ITP
    Randomized Phase III Trial of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Previously Treated Chronic ITP
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2017

    Expires: December 14, 2018

  • Rozanolixizumab in ITP
    Phase II Interim Analysis of FcRn Inhibitor Rozanolixizumab in Adult Patients With Primary Immune Thrombocytopenia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2017

    Expires: December 19, 2018

Supporters

This activity is supported by independent educational grants from

Novartis Pharmaceuticals Corporation